Send Story by Email

Moderna, Inc. (Nasdaq: MRNA) reported the results of its Phase 3 study of mRNA-1273 has --

11-17-2020 • https://www.nextbigfuture.com by Brian Wang

--met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.

Your First Name

Your Last Name

Your Email Address

Enter one or more email addresses below. Separate multiple addresses with a semicolon (;) or a new line. Maximum 10 email addresses at one time.

To Email Address(es)

Personal Note

Also Send Daily Headlines Newsletter